指南与共识其他结缔组织病

2016 ACR/EULAR 成人皮肌炎与多发性肌炎最小、中等和重大临床应答标准

2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative.
指南 / 共识 · Ann Rheum Dis · 2017-01-01

该标准由国际肌炎评估与临床研究组等协作制定,基于6项核心组套指标的绝对百分比变化构建联合分析模型,得出总改善评分(0-100分),以≥20、≥40、≥60分定义最小、中等和重大改善。在皮肌炎/多发性肌炎患者队列中,三个等级的敏感度分别为85%、90%、92%,特异度分别为92%、96%、98%,并在临床试验中验证可区分医生评定的改善(p<0.001)。

要点

  • 总改善评分基于6项核心指标绝对百分比变化及相对权重求和,范围0-100分。
  • 最小、中等、重大改善阈值分别为总改善评分≥20、≥40、≥60分。
  • 验证队列中三个等级敏感度85%-92%,特异度92%-98%。

核心结论

  • 成人皮肌炎和多发性肌炎的应答标准由基于6项核心组套指标绝对百分比变化的联合分析模型构成,并以总改善评分阈值定义最小、中等和重大改善。

研究设计与样本

  • 通过专家调查、逻辑回归和联合分析开发了287个使用核心组套指标的定义,并使用PAPRIKA方法确定核心组套指标的相对权重和联合分析定义。
  • 在患者档案上以专家共识(金标准)评估定义性能特征,并使用临床试验数据进行验证,采用名义群体技术达成共识。

主要发现

  • 共识达成基于联合分析的连续模型,使用核心组套指标(医生、患者和肌肉外整体活动度、肌力、健康评估问卷和肌酶水平)的绝对百分比变化。
  • 总改善评分(范围0-100)通过各核心组套指标改善程度与相对权重求和确定。
  • 在皮肌炎/多发性肌炎患者队列中,最小、中等和重大改善的敏感度分别为85%、90%、92%,特异度分别为92%、96%、98%。
  • 临床试验分析验证了定义可区分医生评定的改善(p<0.001)。

关键数值与推荐

  • 最小改善阈值:总改善评分≥20分;中等改善阈值:总改善评分≥40分;重大改善阈值:总改善评分≥60分。

临床怎么用

  • 临床可使用总改善评分(0-100分)及≥20、≥40、≥60分阈值评估成人皮肌炎和多发性肌炎患者的最小、中等和重大临床应答。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

To develop response criteria for adult dermatomyositis (DM) and polymyositis (PM). Expert surveys, logistic regression, and conjoint analysis were used to develop 287 definitions using core set measures. Myositis experts rated greater improvement among multiple pairwise scenarios in conjoint analysis surveys, where different levels of improvement in 2 core set measures were presented. The PAPRIKA (Potentially All Pairwise Rankings of All Possible Alternatives) method determined the relative weights of core set measures and conjoint analysis definitions. The performance characteristics of the definitions were evaluated on patient profiles using expert consensus (gold standard) and were validated using data from a clinical trial. The nominal group technique was used to reach consensus. Consensus was reached for a conjoint analysis-based continuous model using absolute per cent change in core set measures (physician, patient, and extramuscular global activity, muscle strength, Health Assessment Questionnaire, and muscle enzyme levels). A total improvement score (range 0-100), determined by summing scores for each core set measure, was based on improvement in and relative weight of each core set measure. Thresholds for minimal, moderate, and major improvement were ≥20, ≥40, and ≥60 points in the total improvement score. The same criteria were chosen for juvenile DM, with different improvement thresholds. Sensitivity and specificity in DM/PM patient cohorts were 85% and 92%, 90% and 96%, and 92% and 98% for minimal, moderate, and major improvement, respectively. Definitions were validated in the clinical trial analysis for differentiating the physician rating of improvement (p<0.001). The response criteria for adult DM/PM consisted of the conjoint analysis model based on absolute per cent change in 6 core set measures, with thresholds for minimal, moderate, and major improvement.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Aggarwal R, Rider LG, Ruperto N, et al. 2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Ann Rheum Dis. 2017. PMID: 28385805. doi:10.1136/annrheumdis-2017-211400

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。